RELAY THERAPEUTICS INC (RLAY) Stock Price, Forecast & Analysis
USA - NASDAQ:RLAY - US75943R1023 - Common Stock
RLAY Key Statistics, Chart & Performance
The current stock price of RLAY is 6.45 USD. In the past month the price decreased by -0.92%. In the past year, price increased by 26.35%.
RLAY Latest News, Press Relases and Analysis
RLAY Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 24.58 | 410.35B | ||
| AMGN | AMGEN INC | 15.36 | 180.89B | ||
| GILD | GILEAD SCIENCES INC | 15.29 | 155.35B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 25.03 | 111.41B | ||
| REGN | REGENERON PHARMACEUTICALS | 15.44 | 73.66B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | 890.14 | 59.51B | ||
| INSM | INSMED INC | N/A | 40.36B | ||
| NTRA | NATERA INC | N/A | 27.54B | ||
| BIIB | BIOGEN INC | 9.84 | 24.15B | ||
| INCY | INCYTE CORP | 16.42 | 20.58B | ||
| UTHR | UNITED THERAPEUTICS CORP | 17.52 | 20.91B | ||
| NBIX | NEUROCRINE BIOSCIENCES INC | 34.49 | 14.30B |
Related stock screener links
About RLAY
Company Profile
Relay Therapeutics, Inc. engages in transforming the drug discovery process with an initial focus on enhancing small molecule therapeutic discovery in targeted oncology. The company is headquartered in Cambridge, Massachusetts and currently employs 197 full-time employees. The company went IPO on 2020-07-16. The Company’s initial focus is on enhancing small molecule therapeutic discovery in targeted oncology and genetic disease indications. Its Dynamo platform integrates an array of computational and experimental approaches designed to drug protein targets that have previously been intractable or inadequately addressed. The Company’s lead product candidates, such as RLY-2608. The company is advancing a pipeline of medicine candidates to address targets in precision oncology and genetic disease, including RLY-2608. RLY-2608 is an allosteric, pan-mutant and isoform-selective phosphoinostide 3 kinase alphas (PI3Kα), inhibitor in clinical development. The company is the lead program in its efforts to discover and develop mutant selective inhibitors of PI3Kα.
Company Info
RELAY THERAPEUTICS INC
60 Hampshire Street
Cambridge MASSACHUSETTS 02139 US
CEO: Sanjiv K. Patel
Employees: 197
Phone: 16173708837
RELAY THERAPEUTICS INC / RLAY FAQ
Can you describe the business of RELAY THERAPEUTICS INC?
Relay Therapeutics, Inc. engages in transforming the drug discovery process with an initial focus on enhancing small molecule therapeutic discovery in targeted oncology. The company is headquartered in Cambridge, Massachusetts and currently employs 197 full-time employees. The company went IPO on 2020-07-16. The Company’s initial focus is on enhancing small molecule therapeutic discovery in targeted oncology and genetic disease indications. Its Dynamo platform integrates an array of computational and experimental approaches designed to drug protein targets that have previously been intractable or inadequately addressed. The Company’s lead product candidates, such as RLY-2608. The company is advancing a pipeline of medicine candidates to address targets in precision oncology and genetic disease, including RLY-2608. RLY-2608 is an allosteric, pan-mutant and isoform-selective phosphoinostide 3 kinase alphas (PI3Kα), inhibitor in clinical development. The company is the lead program in its efforts to discover and develop mutant selective inhibitors of PI3Kα.
Can you provide the latest stock price for RELAY THERAPEUTICS INC?
The current stock price of RLAY is 6.45 USD. The price increased by 4.54% in the last trading session.
Does RLAY stock pay dividends?
RLAY does not pay a dividend.
What is the ChartMill rating of RELAY THERAPEUTICS INC stock?
RLAY has a ChartMill Technical rating of 7 out of 10 and a ChartMill Fundamental rating of 4 out of 10.
What is the analyst forecast for RLAY stock?
18 analysts have analysed RLAY and the average price target is 13.87 USD. This implies a price increase of 115.07% is expected in the next year compared to the current price of 6.45.
Can you provide the growth outlook for RELAY THERAPEUTICS INC?
The Revenue of RELAY THERAPEUTICS INC (RLAY) is expected to decline by -19.63% in the next year. Check the estimates tab for more information on the EPS, Sales, EBIT and EBITDA future analyst estimates.
What is the outstanding short interest for RELAY THERAPEUTICS INC?
The outstanding short interest for RELAY THERAPEUTICS INC (RLAY) is 15.58% of its float.
RLAY Technical Analysis
ChartMill assigns a technical rating of 7 / 10 to RLAY. When comparing the yearly performance of all stocks, RLAY is one of the better performing stocks in the market, outperforming 93.5% of all stocks.
RLAY Fundamental Analysis
ChartMill assigns a fundamental rating of 4 / 10 to RLAY. While RLAY has a great health rating, there are worries on its profitability.
RLAY Financial Highlights
Over the last trailing twelve months RLAY reported a non-GAAP Earnings per Share(EPS) of -1.75. The EPS increased by 32.95% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -44.42% | ||
| ROE | -48.97% | ||
| Debt/Equity | 0 |
RLAY Forecast & Estimates
18 analysts have analysed RLAY and the average price target is 13.87 USD. This implies a price increase of 115.07% is expected in the next year compared to the current price of 6.45.
For the next year, analysts expect an EPS growth of 27.56% and a revenue growth -19.63% for RLAY